NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
— Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths – with 90% involving syntheticopioids like fentanyl — Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction. — Mazindol ER is patent protected beyond September 2038 NLS Pharmaceutics Ltd.(NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or […]